We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+10.01%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$466M
AUM Growth
-$255M
Cap. Flow
-$296M
Cap. Flow %
-63.44%
Top 10 Hldgs %
56.9%
Holding
92
New
18
Increased
13
Reduced
21
Closed
28

Top Buys

Rank Stock Value
1
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$9.79M
2
FIVN icon
FIVE9
FIVN
+$5.96M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$5.67M
4
GNRC icon
Generac Holdings
GNRC
+$5.66M
5
ATXS
Astria Therapeutics
ATXS
+$4.84M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$41.8M
2
AZN icon
AstraZeneca
AZN
+$31.2M
3
SNY icon
Sanofi
SNY
+$28.8M
4
NVO
Novo Nordisk
NVO
+$26.4M
5
MRK icon
Merck
MRK
+$25.2M

Sector Composition

Rank Sector Weight
1 Healthcare 60.42%
2 Technology 2.22%
3 Industrials 2%
4 Communication Services 0.09%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALT icon
26
Altimmune
ALT
$552M
$6.26M 1.34%
380,298
-220,000
-37% -$2.47M
CNCE
27
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$5.86M 1.26%
1,002,783
+50,000
+5% +$263K
XBI icon
28
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$5.81M 1.25%
+70,000
New +$5.67M
GNRC icon
29
Generac Holdings
GNRC
$11.6B
$5.03M 1.08%
+50,000
New +$5.66M
MRUS
30
DELISTED
Merus
MRUS
$4.9M 1.05%
316,993
+3,667
+1% +$64.6K
KNSA icon
31
Kiniksa Pharmaceuticals
KNSA
$5.8B
$4.6M 0.99%
+307,283
New +$4.47M
DRS icon
32
Leonardo DRS
DRS
$12.3B
$4.29M 0.92%
+335,557
New +$3.89M
ISEE
33
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.19M 0.9%
195,591
-386,238
-66% -$8.24M
BLU
34
DELISTED
BELLUS Health Inc.
BLU
$4.03M 0.86%
489,860
+25,000
+5% +$233K
RIGL icon
35
Rigel Pharmaceuticals
RIGL
$681M
$3.42M 0.73%
227,885
+11,626
+5% +$107K
KDNY
36
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$3.33M 0.72%
127,200
-407,158
-76% -$9.02M
APLS
37
PUT
DELISTED
Apellis Pharmaceuticals
APLS
$3.1M 0.67%
+60,000
New +$3.18M
CAMT icon
38
Camtek
CAMT
$6.18B
$2.42M 0.52%
+110,000
New +$2.54M
RZLT icon
39
Rezolute
RZLT
$454M
$2.39M 0.51%
1,155,897
– –
ETNB
40
DELISTED
89bio
ETNB
$2.3M 0.49%
180,600
-478,184
-73% -$4.3M
BIIB icon
41
Biogen
BIIB
$30B
$2.08M 0.45%
7,516
-47,984
-86% -$13.6M
STOK icon
42
Stoke Therapeutics
STOK
$1.8B
$1.74M 0.37%
188,640
+31,440
+20% +$327K
INZY
43
DELISTED
Inozyme Pharma
INZY
$1.71M 0.37%
1,625,058
+450,000
+38% +$786K
PMVP icon
44
PMV Pharmaceuticals
PMVP
$59.2M
$1.63M 0.35%
187,800
– –
BCAB icon
45
BioAtla
BCAB
$5.46M
$1.54M 0.33%
+3,732
New +$1.55M
ALPN
46
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.47M 0.32%
200,000
– –
HOWL icon
47
Werewolf Therapeutics
HOWL
$17.2M
$1.28M 0.28%
626,810
– –
MDWD icon
48
MediWound
MDWD
$181M
$1.02M 0.22%
75,413
-22,975
-23% -$233K
AUTL
49
Autolus Therapeutics
AUTL
$407M
$950K 0.2%
+500,000
New +$1.26M
AMAT icon
50
Applied Materials
AMAT
$403B
$828K 0.18%
+8,499
New +$816K
1
2
3 4

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2022 Portfolio in Review

As of Q4 2022, Sphera Funds Management held 92 positions worth $466M, down 35% from $720M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Sphera Funds Management withdrew a net $296M in Q4 2022, closing 28 positions and reducing 21 holdings. Its most notable exit was Palo Alto Networks, an estimated $10.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 66% a quarter earlier, followed by Technology and Industrials.

Against the trend, Sphera Funds Management opened a new position in FIVE9 worth $6.45M.

  • Sphera Funds Management's largest Q4 2022 buy was FIVE9: 95,000 shares worth $6.45M.
  • Sphera Funds Management added most to CinCor Pharma, Inc. Common Stock in Q4 2022, an estimated $9.79M increase.
  • Sphera Funds Management's biggest Q4 2022 reduction was Eli Lilly, cutting an estimated $41.8M.
  • Sphera Funds Management fully exited Palo Alto Networks in Q4 2022, selling an estimated $10.3M.
  • Sphera Funds Management's ten largest holdings make up 57% of its $466M portfolio in Q4 2022.
  • Sphera Funds Management opened 18 new positions and closed 28 in Q4 2022.
  • Sphera Funds Management's portfolio value fell 35% quarter-over-quarter to $466M.

Based on Sphera Funds Management's 13F filing for Q4 2022, filed 14 Feb 2023.